Journal
CLINICA CHIMICA ACTA
Volume 480, Issue -, Pages 199-205Publisher
ELSEVIER
DOI: 10.1016/j.cca.2018.02.019
Keywords
Multiple myeloma; H19; Serum; Biomarker; Diagnosis
Categories
Funding
- Jiangsu Provincial Funds for Six Categories of Top Talents [WS-066]
- Jiangsu Provincial Health and Family Planning Commission [H201526]
Ask authors/readers for more resources
Circulating long noncoding RNA (lncRNA) H19 has been reported to be a biomarker for cancer monitoring. The purpose of this study was to determine whether serum lncRNA could serve as a novel biomarker for the diagnosis of multiple myeloma (MM) and evaluate its value of clinical application. In our study, the expression of lncRNA H19 was up-regulated in 80 patients with MM and MM cell lines by RT-PCR analysis. Clinicopathological analysis showed the expression level of H19 could assist clinical staging, and the severity of the disease could be roughly determined according to the amount of H19 expressed in the patient serum. This is the first report to show that H19 was expressed in the serum of MM patients, suggesting that upregulation of serum lncRNA 1119 may prove to be a novel biomarker for early diagnosis and clinical treatment of MM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available